E-LIB Suche - Ergebnisse für: Dreyling, M.

1

Primary central nervous system lymphomas: EHA–ESMO Clinical..:

Ferreri, A.J.M. ; Illerhaus, G. ; Doorduijn, J.K....
Annals of Oncology. 35 (2024) 6 - p. 491-507 , 2024

Link: https://doi.org/10.1016/..

2

LONG-TERM DURABLE RESPONSES IN PATIENTS (PTS) WITH RELAPSED..:

Awasthi, R. ; Waldron, E. ; Grupp, S.A....
Cytotherapy. 26 (2024) 6 - p. S152 , 2024

Link: https://doi.org/10.1016/..

3

UNMET NEED IN RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOM..:

Dreyling, M. ; Shah, B. ; Wu, J....
Hematological Oncology. 41 (2023) S2 - p. 755-757 , 2023

Link: https://doi.org/10.1002/..

4

Five‐year subgroup analysis of tafasitamab + lenalidomide f..:

Duell, J. ; Abrisqueta, P. ; Dreyling, M....
Hematological Oncology. 41 (2023) S2 - p. 439-441 , 2023

Link: https://doi.org/10.1002/..

5

CONSOLIDATIVE HCT‐ASCT IS SUPERIOR TO NON‐MYELOABLATIVE CHE..:

Illerhaus, G. ; Ferreri, A. ; Binder, M....
Hematological Oncology. 41 (2023) S2 - p. 41-43 , 2023

Link: https://doi.org/10.1002/..

6

CELL‐FREE DNA KINETICS DECIPHER POTENTIAL MECHANISMS OF ACT..:

Khouja, M. ; Genuardi, E. ; Ferrero, S....
Hematological Oncology. 41 (2023) S2 - p. 181-183 , 2023

Link: https://doi.org/10.1002/..

7

HIGH RATE OF METABOLIC COMPLETE RESPONSE AFTER LOW DOSE RAD..:

Herfarth, K. ; Scholz, C. W. ; Hübel, K....
Hematological Oncology. 41 (2023) S2 - p. 218-220 , 2023

Link: https://doi.org/10.1002/..

8

TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALE..:

Morschhauser, F. ; Dahiya, S. ; Palomba, M. L....
Hematological Oncology. 41 (2023) S2 - p. 877-880 , 2023

Link: https://doi.org/10.1002/..

9

Final safety and efficacy results of copanlisib monotherapy..:

Dreyling, M. ; Santoro, A. ; Mollica, L....
Hematological Oncology. 41 (2023) S2 - p. 560-562 , 2023

Link: https://doi.org/10.1002/..

10

EPH163 Burden of Diffuse Large B-Cell Lymphoma (DLBCL) in G..:

Moertl, B ; Beier, D ; Schmidt, C...
Value in Health. 25 (2022) 12 - p. S222 , 2022

Link: https://doi.org/10.1016/..

11

P1438: PROCALCITONIN IS ELEVATED IN SEVERE INFECTIONS AFTER..:

Rejeski, K. ; Blumenberg, V. ; Hildebrand, F....
HemaSphere. 6 (2022) - p. 1321-1322 , 2022

Link: https://doi.org/10.1097/..

12

P1154: STUDY ZILO-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND,..:

Yazji, S. ; Hamburger, S. ; Wang, Y....
HemaSphere. 6 (2022) - p. 1041-1042 , 2022

Link: https://doi.org/10.1097/..

13

SA29 Efficacy Outcomes Following Treatment with Bruton Tyro..:

Dreyling, M ; Shah, B ; Wu, JJ...
Value in Health. 25 (2022) 7 - p. S609-S610 , 2022

Link: https://doi.org/10.1016/..

14

P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUD..:

Eyre, T. A. ; Shah, N. N. ; Le Gouill, S....
HemaSphere. 6 (2022) - p. 990-991 , 2022

Link: https://doi.org/10.1097/..

15

Managing hematological cancer patients during the COVID-19 ..:

Buske, C. ; Dreyling, M. ; Alvarez-Larrán, A....
ESMO Open. 7 (2022) 2 - p. 100403 , 2022

Link: https://doi.org/10.1016/..